QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

NCT07009145 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Colorectal Cancer
Metastatic Colorectal Cancer (CRC)
MSI-H/dMMR Colorectal Cancer

Interventions

DRUG: QL1706
DRUG: Bevacizumab

Sponsor

Qianfoshan Hospital

Collaborators

[object Object]
[object Object]
[object Object]